Trial · NCT07912775
Transcranial Direct Current Stimulation for Chemotherapy-Related Chronic Pain in Cancer Survivors
NCT07912775, Not applicable, Not yet recruiting, Instituto de investigación e innovación biomédica de Cádiz
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Transcranial Direct Current Stimulation for Chemotherapy-Related Chronic Pain in Cancer Survivors. Trials, record NCT07912775. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07912775
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Transcranial Direct Current Stimulation for Chemotherapy-Related Chronic Pain in Cancer Survivors
- NCT number
- NCT07912775
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 60 participants, estimated
- Lead sponsor
- Instituto de investigación e innovación biomédica de Cádiz
- Conditions
- Chronic Pain, Neuropathic Pain, Cancer Survivors, Anxiety, Depression, Cognitive Dysfunction, Chemotherapy-Related Chronic Pain
- Interventions
- Active tDCS with Sternberg task, Sham tDCS with Sternberg task
- First posted
- 2026-11-03
- Last updated
- 2026-11-03
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in pain intensity (Visual Analogue Scale, VAS) after the acute phase | Baseline (T0) and after the acute phase at 1 week (T1) | Change from baseline in pain intensity measured with the Visual Analogue Scale (VAS), comparing active tDCS with sham tDCS. Scores range from 0 (no pain) to 10 (worst imaginable pain); higher scores indicate a worse outcome. Responders are defined as participants with a reduction of at least 2 points from baseline. |
| Secondary | Change in pain intensity (Visual Analogue Scale, VAS) from the end of the acute phase through maintenance | From the end of the acute phase at 1 week (T1) to the end of maintenance at up to 2 months (T4) | Change in pain intensity measured with the Visual Analogue Scale (VAS), relative to baseline, from the end of the acute phase through the end of maintenance (assessed at T2, T3, and T4). Scores range from 0 (no pain) to 10 (worst imaginable pain); higher scores indicate a worse outcome. |
| Secondary | Change in pain severity and interference (Brief Pain Inventory, BPI) | Baseline (T0), 1 week (T1), 2 weeks (T2), 1 month of maintenance (T3), and end of maintenance at up to 2 months (T4) | Change from baseline in pain severity and pain interference with daily functioning measured with the Brief Pain Inventory - Short Form (BPI-SF). The severity score (mean of 4 items) and the interference score (mean of 7 items) each range from 0 to 10; higher scores indicate greater severity and interference (worse outcome). |
| Secondary | Change in anxiety and depression (Hospital Anxiety and Depression Scale, HADS) | Baseline (T0), 1 week (T1), 2 weeks (T2), 1 month of maintenance (T3), and end of maintenance at up to 2 months (T4) | Change from baseline in anxiety and depression symptoms, measured with the 14-item Hospital Anxiety and Depression Scale (HADS). The anxiety and depression subscales each range from 0 to 21; higher scores indicate more severe symptoms (worse outcome). |
| Secondary | Change in global cognitive function (Montreal Cognitive Assessment, Spanish version, MoCA-S) | Baseline (T0), 1 week (T1), 2 weeks (T2), 1 month of maintenance (T3), and end of maintenance at up to 2 months (T4) | Change from baseline in global cognitive function, measured with the Spanish version of the Montreal Cognitive Assessment (MoCA-S). Total scores range from 0 to 30; higher scores indicate better cognitive function (better outcome). |
| Secondary | Change in information processing speed (Symbol Digit Modalities Test, SDMT) | Baseline (T0), 1 week (T1), 2 weeks (T2), 1 month of maintenance (T3), and end of maintenance at up to 2 months (T4) | Change from baseline in information processing speed and attention measured with the written Symbol Digit Modalities Test (SDMT), scored as the number of correct responses in 90 seconds. Scores range from 0 to 110; higher scores indicate better performance (better outcome). |
| Secondary | Change in sustained attention and working memory (Paced Auditory Serial Addition Test, PASAT-3) | Baseline (T0), 1 week (T1), 2 weeks (T2), 1 month of maintenance (T3), and end of maintenance at up to 2 months (T4) | Change from baseline in sustained and divided attention and working memory measured with the 3-second version of the Paced Auditory Serial Addition Test (PASAT-3), scored as the number of correct responses. Scores range from 0 to 60; higher scores indicate better performance (better outcome). |
| Secondary | Change in verbal fluency (Controlled Oral Word Association Test, COWAT) | Baseline (T0), 1 week (T1), 2 weeks (T2), 1 month of maintenance (T3), and end of maintenance at up to 2 months (T4) | Change from baseline in executive function and semantic and phonemic verbal fluency measured with the Controlled Oral Word Association Test (COWAT), scored as the total number of correct words generated (60 seconds per letter or category). The minimum score is 0 and there is no fixed maximum; higher scores indicate better performance (better outcome). |
| Secondary | Change in verbal learning and memory (Rey Auditory Verbal Learning Test, RAVLT) | Baseline (T0), 1 week (T1), 2 weeks (T2), 1 month of maintenance (T3), and end of maintenance at up to 2 months (T4) | Change from baseline in verbal learning and short- and long-term auditory-verbal memory measured with the Rey Auditory Verbal Learning Test (RAVLT). Total learning across trials 1-5 ranges from 0 to 75; immediate (post-interference) and delayed recall each range from 0 to 15; higher scores indicate better performance (better outcome). |
| Secondary | Change in quality of life (World Health Organization Quality of Life - Brief Version, WHOQOL-BREF) | Baseline (T0), 1 week (T1), 2 weeks (T2), 1 month of maintenance (T3), and end of maintenance at up to 2 months (T4) | Change from baseline in quality of life measured with the 26-item World Health Organization Quality of Life - Brief Version (WHOQOL-BREF). Physical, psychological, social relationships and environment domain scores are transformed to a 0-100 scale; higher scores indicate better quality of life (better outcome). |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests4
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Paced Visual Serial Addition Test | Secondary outcome | ConductCognition |
| Symbol Coding | Secondary outcome | ConductCognition |
| Verbal Fluency | Secondary outcome | ConductCognition |
| Verbal Learning | Secondary outcome | ConductCognition |
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07912775
GET https://conductscience.org/api/trials/v1/NCT07912775/registered